First Global Downgrades Teva Pharma (TEVA) to Market Perform, Poor Laquinimod Phase III Drug Trial Results
Go back to First Global Downgrades Teva Pharma (TEVA) to Market Perform, Poor Laquinimod Phase III Drug Trial Results| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 37.47 +0.89 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.58 | 52 Week High | $66.55 | |||
| Open | $37.00 | 52 Week Low | $37.82 | |||
| Day High | $37.83 | P/E | N/A | |||
| Day Low | $36.60 | EPS | $0.00 | |||
| Volume | 7,964,326 | |||||
